CD19 and mantle cell lymphoma: ZUMA-2 is a multicenter phase II trial which evaluated KTE-X19, a product which shares the same design of axi-cel but which is obtained in a different manufacturing process removing CD19-positive malignant cells, in patients with R/R mantle cell lymphoma (MCL).